|
Company:
|
TYME TECHNOLOGIES, INC. (TYME)
|
|
Form Type:
|
4
|
|
Filing Date:
|
6/11/2020
|
|
CIK:
|
0001537917
|
|
Address:
|
1 PLUCKEMIN WAY - SUITE 103
|
|
City, State, Zip:
|
BEDMINSTER, New Jersey 07921
|
|
Telephone:
|
212-461-2315
|
|
Fiscal Year:
|
03/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$1.78
|
Change:
-0.13 (-6.81%)
|
Trade Time:
Jan 27
|
Market Cap:
$231.71M
|
|
|
|
|
|
|
Description of Business
|
|
TYME is an emerging biotechnology company developing cancer metabolism-based
therapies (CMBTsTM) that are intended to be effective across a broad range of
solid tumors and hematologic cancers, while also maintaining patients' quality
of life through relatively low toxicity profiles. Unlike targeted therapies that
attempt to regulate specific pathways within cancer, TYME's therapeutic approach
is designed to take advantage of a cancer cell's innate metabolic requirements
to cause cancer cell death. Our first-in-class CMBT compounds include SM-88 and
TYME-18. These compounds are structurally and mechanistically different, and we
believe they offer the potential for better and safer medicines. Early clinical
results demonstrated by SM-88 in multiple advanced cancers, including
pancreatic, prostate, sarcomas and breast, reinforce the potential of our
emerging CMBT pipeline.
|
|
|
|